PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISAESE (MASLD)-RELATED CIRRHOSIS IN THE UNITED STATES

被引：0
|
作者：
Owrangi, Soroor
Hashida, Ryuki
Paik, James M.
Golabi, Pegah
De Avila, Leyla
Younossi, Zobair M.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1580
引用
收藏
页码：S1648 / S1649
页数：2
相关论文
共 50 条
  • [21] RACIAL/ETHNIC DISPARITIES IN RISKS OF CIRRHOSIS AMONG VETERANS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN THE UNITED STATES
    Wong, Robert
    Yang, Zeyuan
    Singal, Ashwani
    Pessoa, Mario
    Krag, Aleksander
    Schattenberg, Joern
    Henry, Linda
    Alqahtani, Saleh
    Lazarus, Jeffrey
    Younossi, Zobair
    HEPATOLOGY, 2024, 80 : S692 - S693
  • [22] Cardioprotective Role of Beta Hydroxybutyrate in Metabolic Dysfunction -Associated Steatotic Liver Disease (MASLD)
    Badmus, Olufunto
    da Silva, Alexandre
    Taylor, Lucy
    Greer, Jennifer
    McGowan, Karis
    PHYSIOLOGY, 2024, 39
  • [23] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [24] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [25] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [26] PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS
    Miele, L.
    De Simone, C.
    Cefalo, C.
    Vallone, S.
    Bussoletti, C.
    Forgione, A.
    Gabrieli, M. L.
    Vero, V.
    Di Stasi, C.
    D'Agostino, M.
    Amerio, P.
    Gasbarrini, G.
    Grieco, A.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S179 - S179
  • [27] Exploring Autoantibodies as Predictors of Severe Fibrosis or Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Response
    Faisal, Nabiha
    Minuk, Gerald
    CANADIAN LIVER JOURNAL, 2024, 7 (04): : 417 - 418
  • [28] CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN SWEDEN
    Shang, Ying
    Zhang, Xiao
    Fernandes, Gail
    Melaragno, Matthew
    Engel, Samuel
    Vessby, Johan
    Ekstedt, Mattias
    Hagstrom, Hannes
    HEPATOLOGY, 2024, 80 : S821 - S822
  • [29] POOR LIVER DISEASE AWARENESS AMONG ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE UNITED STATES
    Biswas, Rakesh
    Paik, James M.
    Arshad, Tamoore
    Golabi, Pegah
    Henry, Linda
    Younossi, Zobair M.
    HEPATOLOGY, 2020, 72 : 403A - 403A
  • [30] The Utilization of Non-Invasive Tests (NITs) for the Clinical Management of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the United States
    Allen, Alina
    Alkhouri, Naim
    Nouredden, Mazen
    Wai-Sun Wong, Vincent
    Tsochatzis, Emmanuel
    Deavila, Leyla
    Racila, Andrei
    Stepanova, Maria M.
    Nader, Fatema
    Mark, Henry
    Lazarus, Jeffrey
    Castera, Laurent
    Younossi, Zobair
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1385 - S1385
12345